BMEA250117P5500
- 0.00
- 0.000.00%
Biomea Fusion Newsroom
Barclays Maintains Biomea Fusion(BMEA.US) With Hold Rating, Maintains Target Price $11
Analysts Offer Insights on Healthcare Companies: Boston Scientific (BSX), Biomea Fusion (BMEA) and Solid Biosciences (SLDB)
Scotiabank Maintains Biomea Fusion(BMEA.US) With Buy Rating, Cuts Target Price to $30
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study
Here's Why Biomea Fusion, Inc. (NASDAQ:BMEA) Is Among the Best Diabetes Stocks to Buy Under $10
Biomea Fusion to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Biomea Fusion Advances Diabetes Treatment With Positive Study Results
Truist Financial Maintains Biomea Fusion(BMEA.US) With Buy Rating
Express News | Biomea Fusion Inc : Scotiabank Cuts Target Price to $30 From $41
A Quick Look at Today's Ratings for Biomea Fusion(BMEA.US), With a Forecast Between $11 to $50
Barclays Remains a Hold on Biomea Fusion (BMEA)
Cautious Hold Rating on Biomea Fusion Amid Uncertainties in Drug Efficacy and Financial Outlook
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Why Is Diabetes-Drug Developer Biomea Fusion Stock Trading Lower On Tuesday?
Biomea Stock Sinks 16% After Phase 2 Data Release
Biomea Fusion Shares Are Trading Lower. The Company Reported Phase II Results for Icovamenib in Type 2 Diabetes.
Express News | Biomea Fusion Inc - Icovamenib Meets Primary Endpoint With Significant Reduction in Hba1C
What's Driving Biomea Fusion? Stock Soars 25%
Biomea Fusion to Host Conference Call to Announce Topline Results From Phase II COVALENT-111 Study in Patients With Type 2 Diabetes (T2D)
HC Wainwright & Co. Reiterates Buy on Biomea Fusion, Maintains $40 Price Target